Thus, clinical trials conclude that combination therapy with standard chemotherapy drugs (i.e., cytarabine and daunorubicin) show a better therapeutic response for NPM1-mutant AML with a better-predicted response rate for FLT3-ITD positive patients [158]. This evidence concerns the gene FLT3 and acute myeloid leukemia.